暗号関連株
Hyperion DeFi
2025/12/7(日) 15:12:18
logo
Hyperion DeFi
NASDAQ · $HYPD
Crypto Strategic Reserve
$3.92
--
会社情報

Hyperion DeFi, Inc. is an ophthalmic technology company engaged in the development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a platform service for the localized delivery of ophthalmic medications. The company has entered into a licensing agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a licensing agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; a licensing agreement with Kaken Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and an agreement with Formosa Pharmaceuticals, Inc. to co-develop a chlorobetasol propionate ophthalmic suspension (0.05%) for the treatment of acute dry eye disease in the United States. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is headquartered in New York City, New York.

暗号通貨保有状況
HYPE
币种储备情况
As of July 2025, Hyperion DeFi holds 1,427,178 HYPE tokens, with an average purchase cost of $35.38 per token.
QRコードを長押ししてより多くのコンテンツを表示
Hyperion DeFi

Hyperion DeFi

$HYPDNASDAQ
Crypto Strategic Reserve

企業情報

Hyperion DeFi, Inc. is an ophthalmic technology company engaged in the development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a platform service for the localized delivery of ophthalmic medications. The company has entered into a licensing agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a licensing agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; a licensing agreement with Kaken Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and an agreement with Formosa Pharmaceuticals, Inc. to co-develop a chlorobetasol propionate ophthalmic suspension (0.05%) for the treatment of acute dry eye disease in the United States. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is headquartered in New York City, New York.
CEO
Michael M. Rowe
設立
2025
本社所在地
New York City, New York State
取引所
NASDAQ
H
年間最高値
$15.40
L
年間最安値
$3.50

株価チャート

ビジネスモデル

ビジネスモード

Hyperion DeFi's main business revolves around the HYPE token, aiming to become the first publicly listed company in the United States to provide investors with compliant investment channels to the Hyperliquid protocol through holding HYPE. The company continuously increases its holdings of HYPE tokens and plans to deploy them on the HyperCore and HyperEVM platforms to generate potential revenue sources. Additionally, the company has partnered with Kinetiq to launch co-branded verification nodes on the Hyperliquid blockchain, utilizing HYPE tokens to support network security.

利益モデル

Hyperion DeFi profits by using the reserved HYPE for staking, lending, and expanding node operations and referral commission businesses. At the same time, as the value of the HYPE token increases, the value of the assets held by the company also rises, which may allow for profits through the timely sale of some tokens. Additionally, as a publicly listed company, the increase in its stock price can also bring about an increase in market capitalization, attracting more investors, which in turn provides more funds for increasing holdings of HYPE tokens, creating a virtuous cycle.

利益モデルの影響

This profit model helps Hyperion DeFi establish a competitive advantage in the cryptocurrency field. By participating in the business of the Hyperliquid ecosystem, it can obtain a stable source of income, enhancing the company's profitability. At the same time, it provides investors with a compliant channel to participate in cryptocurrency asset investments, which is beneficial for attracting more institutional investors, connecting traditional capital markets with decentralized finance, and promoting the compliant development and popularization of the cryptocurrency industry.

暗号資産への影響

The main impact is on the HYPE token. The company's continuous accumulation of HYPE tokens will increase market demand for them, driving up the price. Moreover, the company uses HYPE for staking, lending, and other services, expanding its application scenarios within the ecosystem, further enhancing the value and market influence of HYPE. In addition, the company's compliance operations and market influence may also attract more investors' attention to the Hyperliquid protocol, indirectly promoting the development of the HYPE token.

関連ニュース

ソーシャルメディア